Treating autoimmune disorders has been a cash cow for several pharmaceutical companies, with biologics and biosimilars dominating pharma industry news for two decades now. Just days ago, Amgen settled patent infringement litigation with AbbVie, allowing its Humira biosimilar Amjevita to launch in Europe in October 2018, but blocking entry in the US until 2023. And today, Thync released news saying they have demonstrated the first effective use of bioelectronics to treat psoriasis in a 2017 pilot study. So what impact will bioelectronic devices, like the one Thync Global developed, have on the biopharmaceutical industry and the treatment of autoimmune disorders? I think the potential impact will not be insignificant. 

Having conducted considerable research with physicians and patients in psoriasis and across multiple autoimmune disorders, I hear time and again that there is room for additional treatment options to address significant unmet needs. I look forward to a time in the near future when I can ask physicians and patients about their perceptions of a non-invasive bioelectronics wearable with no serious adverse events and low risk side effects (primarily influences on skin). At first blush, the safety and administration profile may be very appealing to some customers versus an IM, sub-Q, or infused biopharmaceutical with a list of potential AEs and side effects. Certainly, wearables such as Thync Global's could be used as an adjunctive treatment, but it feels as though we may be witnessing the rise of a biopharmaceuticals challenger.